🟢 LLY is trading 10.41% up today after a massive Q1 earnings beat and raised full-year guidance

LLY is trading at $939.84 (+10.41%) following a blockbuster Q1 2026 earnings report and an upward revision to its full-year financial outlook.

• The company reported revenue of $19.8 billion (13.7% beat) and adjusted EPS of $8.55 (25.9% beat), driven by a 56% year-over-year surge in demand for obesity and diabetes treatments Mounjaro and Zepbound.
• Management raised full-year 2026 revenue guidance to $82-$85 billion and non-GAAP EPS to $35.50-$37.00, reflecting strong international growth—particularly an 81% jump in sales following expanded Mounjaro access in China.
• Momentum was further bolstered by the FDA approval of obesity treatment Foundayo and a 43% increase in U.S. revenues.